Aquestive Therapeutics is a pharmaceutical company that specializes in innovative drug delivery systems, particularly through its proprietary PharmFilm® technology. This technology allows for the development of oral films that can deliver medications effectively, addressing challenges such as solubility and permeability. The company has a robust pipeline aimed at improving treatment options for patients with complex conditions, including central nervous system disorders and severe allergies. Their approach is characterized by a drug-by-drug strategy, ensuring that each medication is tailored to achieve optimal absorption, bioavailability, and onset of action, thereby enhancing patient outcomes.

In addition to its focus on drug delivery, Aquestive offers comprehensive development and manufacturing services to industry partners. Their capabilities span the entire product lifecycle, from formulation development to commercialization, utilizing a systematic and risk-controlled approach. The company emphasizes collaboration with clinical research organizations and regulatory bodies to ensure that their products meet the highest standards of quality and efficacy. With over 200 patents and a significant number of doses consumed globally, Aquestive is positioned as a leader in the field of oral film technology, committed to advancing therapeutic solutions that improve patients' lives.

United States

Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. 
Aquestive has five commercialized products on the U.S. market, four licensed products and one stand-alone proprietary product to date, Sympazan® (clobazam) oral film for the treatment of seizures associated with Lennox-Gastaut Syndrome. Our licensees market their products in the U.S. and around the world. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. 
Aquestive is advancing a late-stage proprietary product pipeline focused on treating diseases of the central nervous system, or CNS, and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis.



Allergy

Central Nervous System (CNS)

Genetic Diseases

Nervous System Diseases

Pathological Conditions

Aquestive Therapeutics

Seizures

Libervant™ is a buccally, or inside of the cheek, administered soluble film formulation of diazepam, a benzodiazepine intended for rapid treatment of acute uncontrolled seizures in selected, refractory patients with epilepsy on stable regimens of AEDs who require intermittent use of diazepam to control bouts of increased seizure activity. Aquestive is developing Libervant as an alternative to Diastat (diazepam rectal gel), the current standard of care rescue therapy for patients with refractory epilepsy which as, a rectal gel, is invasive, inconvenient, and difficult to administer. As a result, a large portion of the patient population does not receive adequate treatment or foregoes treatment altogether. The Company believes that Libervant will enable a larger share of these patients to receive more appropriate treatment by providing consistent therapeutic dosing in a non-invasive and innovative treatment form for epileptic seizures.

LIBERVANT™ (Diazepam) Buccal Film

Amyotrophic lateral sclerosis

Neurodegenerative disease

The mechanism by which riluzole exerts its therapeutic effects in patients with ALS is unknown.

Exservan™ (riluzole) Oral Film

Cancer

Melanoma

Neurological disorder

Parkinson's disease

KYNMOBI is a non-ergoline dopamine agonist with high in vitro binding affinity for the dopamine D4 receptor, and moderate affinity for the dopamine D2, D3, and D5, and adrenergic α1D, α2B, α2C receptors. The precise mechanism of action of KYNMOBI as a treatment for “off” episodes associated with Parkinson's disease is unknown, although it is believed to be due to stimulation of post-synaptic dopamine D2-type receptors within the caudate-putamen in the brain.

KYNMOBI™ (apomorphine HCI) sublingual film (APL-130277)

Chemotherapy induced nausea and vomiting

Nausea and vomiting

Ondansetron is a selective 5-HT3 receptor antagonist. While its mechanism of action has not been fully characterized, ondansetron is not a dopamine-receptor antagonist. Serotonin receptors of the 5-HT3 type are present both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. It is not certain whether ondansetron’ s antiemetic action is mediated centrally, peripherally, or in both sites. However, cytotoxic chemotherapy appears to be associated with release of serotonin from the enterochromaffin cells of the small intestine. In humans, urinary 5-HIAA (5-hydroxyindoleacetic acid) excretion increases after cisplatin administration in parallel with the onset of emesis. The released serotonin may stimulate the vagal afferents through the 5HT3
receptors and initiate the vomiting reflex. In animals, the emetic response to cisplatin can be prevented by pretreatment with an inhibitor of serotonin synthesis, bilateral abdominal vagotomy and greater splanchnic nerve section, or pretreatment with a serotonin 5-HT3 receptor antagonist.

ZUPLENZ (ondansetron)

Opioid dependence

SUBOXONE sublingual film contains buprenorphine and naloxone. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is a potent antagonist at mu opioid receptors and produces opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists when administered parenterally.

SUBOXONE (buprenorphine/naloxone)

Anaphylaxis

AQST-109 is a polymer matrix-based epinephrine prodrug administered as a &nbsp;sublingual film that is applied under the tongue for the rapid delivery &nbsp;of epinephrine. The product is similar in size to a postage stamp, &nbsp;weighs less than an ounce, and begins to dissolve on contact. No water &nbsp;or swallowing is required for administration. The packaging for AQST-109 &nbsp;is thinner and smaller than an average credit card, can be carried in a &nbsp;pocket, and is designed to withstand weather excursions such as &nbsp;exposure to rain and/or sunlight.

Anaphylm (Epinephrine) Sublingual Film (AQST-109)

Alopecia areata

AQST-108 (epinephrine) Topical Gel

Erectile dysfunction

AQST-109 is a polymer matrix-based epinephrine prodrug administered as a &nbsp;sublingual film that is applied under the tongue for the rapid delivery &nbsp;of epinephrine. The product is similar in size to a postage stamp, &nbsp;weighs less than an ounce, and begins to dissolve on contact. No water &nbsp;or swallowing is required for administration. The packaging for AQST-109 &nbsp;is thinner and smaller than an average credit card, can be carried in a &nbsp;pocket, and is designed to withstand weather excursions such as &nbsp;exposure to rain and/or sunlight.

Aquestive Therapeutics

Company Details